全球帕金森病治疗市场 – 行业趋势及 2030 年预测

帕金森病治疗市场分析及规模

帕金森病是一种比较常见的神经系统疾病，每年每十万人中估计有10人患有帕金森病。帕金森病的发病率随着年龄的增长而增加，大多数病例发生在60岁以上的人群中。帕金森病的发病率也因地区而异，北美和欧洲的发病率高于世界其他地区。据估计，60岁以上的人口中约有1%患有帕金森病，85岁以上的人群中发病率上升到4-5%。值得注意的是，由于帕金森病早期诊断困难，缺乏标准化的诊断标准，其发病率和患病率可能被低估。

Data Bridge Market Research 分析，帕金森病治疗市场规模在 2022 年为 49.9918 亿美元，到 2030 年将飙升至 100.3452 亿美元，预计在预测期内的复合年增长率为 9.10%。这表明了市场价值。由于对神经系统疾病更好治疗的需求不断增长，“左旋多巴/卡比多巴”在帕金森病治疗市场的药物类别中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

帕金森病治疗市场范围和细分

Market Definition

Parkinson’s disease is the combination of progressive, degenerative neurological motor disorder, mainly affecting the dopaminergic cells of the brain. Tremor, rigidity, bradykinesia and postural volatility are some of the common symptoms of Parkinson’s disease.

Global Parkinson’s Diseases Treatment Market Dynamics

Drivers

• Advancements in Drug Development

There have been significant advancements in drug development for Parkinson's disease in recent years, including the development of new therapies that target specific pathways in the disease process. This has led to the introduction of new drugs and treatment options, driving growth in the market.

• Increasing Healthcare Expenditure

The growing healthcare expenditure in both developed and developing countries is expected to drive the growth of the Parkinson's disease treatment market. With increasing access to healthcare and rising awareness about Parkinson's disease, more patients are seeking treatment, driving demand for drugs and therapies.

Opportunities

• Government Initiatives and Funding

Governments around the world are investing in research and development to find new treatments for Parkinson's disease. This funding is driving innovation and helping to bring new treatments to market, further driving growth in the market.

• Improved Diagnostic Tools

The development of improved diagnostic tools for Parkinson's disease presents an opportunity to identify patients at earlier stages of the disease and provide more effective treatment. This could lead to better outcomes and reduce the overall burden of the disease on patients and healthcare systems.

Restraints/Challenges

• High Cost of Treatment

The high cost of treatment and limited awareness and understanding of the disease are the factors that will hinder the market growth and will further challenge Parkinson’s disease treatment. Also, the lack of disease-modifying therapies and limited efficacy of current treatments, the heavy customs duty imposed on medical devices and treatment accessories, and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.

This Parkinson’s disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Parkinson’s disease treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In June 2021, Biogen announced that it had completed the acquisition of TMS-007, a Phase 2-ready asset for the treatment of Parkinson's disease. TMS-007 is a small molecule inhibitor of the leucine-rich repeat kinase 2 (LRRK2) protein, which is believed to play a role in the development of Parkinson's disease
• In May 2021, Roche announced positive Phase 3 trial results for its investigational drug, prasinezumab, for the treatment of Parkinson's disease. Prasinezumab is a monoclonal antibody that targets alpha-synuclein, a protein that is believed to contribute to the development of Parkinson's disease
• In April 2021, AbbVie announced positive Phase 2 trial results for its investigational drug, ABBV-951, for the treatment of Parkinson's disease. ABBV-951 is a levodopa-carbidopa intestinal gel (LCIG) that is delivered via a pump system and is designed to provide continuous delivery of medication to reduce motor fluctuations in Parkinson's disease patients
• In March 2021, Sunovion announced that it had received FDA approval for its drug, Kynmobi, for the treatment of Parkinson's disease. Kynmobi is a sublingual film formulation of apomorphine, a dopamine agonist that is used to treat "off" episodes in Parkinson's disease patients.

Global Parkinson’s Disease Treatment Market Scope

The Parkinson’s disease Treatment market is segmented on the basis of drug class, medical devices, route of administration, distribution channel and patient care setting. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Levodopa/Carbidopa
• Dopamine Receptor Agonists
• MAO-Inhibitors
• COMT-Inhibitors
• Anticholinergics
• Other Drugs

 Medical Devices

• Deep Brain Stimulation (DBS) Devices
• Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices

Route of Administration

• Oral
• Transdermal
• Subcutaneous
• Intestinal Infusion
• Others

Distribution Channel

• Hospital Pharmacies
• Clinics
• Retail Pharmacies
• Online Pharmacies

Patient Care Setting

• Hospitals
• Clinics

Global Parkinson’s Disease Treatment Market Regional Analysis/Insights

The global Parkinson’s disease Treatment market is analyzed and market size insights and trends are provided by country, drug class, medical devices, route of administration, distribution channel, and patient care setting, as referenced above.

The countries covered in the Parkinson’s Disease Treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the Parkinson’s disease treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having neurological diseases, especially Parkinson’s disease.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for neurological diseases, the large population pool, and the growing demand for quality healthcare in the region.

报告的国家部分还提供了影响单个市场影响因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。   

医疗保健基础设施增长安装基础和新技术渗透

帕金森病治疗市场还为您提供了详细的市场分析，包括每个国家在资本设备医疗保健支出的增长情况、帕金森病治疗市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管场景的变化及其对帕金森病治疗市场的影响。

竞争格局和帕金森病市场份额分析

帕金森病治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对帕金森病治疗市场的关注有关。

帕金森病治疗市场的一些主要参与者包括：

• 葛兰素史克公司（英国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 勃林格殷格翰国际有限公司（德国）
• Impax Laboratories LLC（美国）
• AbbVie Inc.（美国）
• Bausch Health。（加拿大）
• 灵北（丹麦）
• 太阳制药工业有限公司 (印度)
• ACADIA Pharmaceuticals Inc.（美国）
• 默克公司（美国）
• 诺华公司（瑞士）
• UCB SA（比利时）
• Dr. Reddy's Laboratories Ltd.（印度）
• WOCKHARDT.（印度）
• F. Hoffmann-La Roche Ltd（瑞士）
• STADA Arzneimittel AG（德国）
• Orion Corporation。（芬兰）
• Mylan NV（英国）
• Cipla Inc.（印度）
• Par Pharmaceutical。（美国）
• 第一三共株式会社（日本）
• Apotex Inc（加拿大）

SKU-28635